Group One Trading’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-23,495
| Closed | -$418K | – | 8400 |
|
|
2023
Q3 | $350K | Buy |
+23,495
| New | +$311K | ﹤0.01% | 3282 |
|
|
2022
Q4 | – | Sell |
-18,932
| Closed | -$72K | – | 8310 |
|
|
2022
Q3 | $66K | Buy |
18,932
+8,218
| +77% | +$29.5K | ﹤0.01% | 5171 |
|
|
2022
Q2 | $32K | Sell |
10,714
-1,677
| -14% | -$4.01K | ﹤0.01% | 5945 |
|
|
2022
Q1 | $39K | Buy |
+12,391
| New | +$39K | ﹤0.01% | 6303 |
|
|
2021
Q3 | – | Sell |
-11,540
| Closed | -$45.5K | – | 8946 |
|
|
2021
Q2 | $50K | Buy |
11,540
+9,897
| +602% | +$43.9K | ﹤0.01% | 6586 |
|
|
2021
Q1 | $7K | Sell |
1,643
-16,807
| -91% | -$90.5K | ﹤0.01% | 7177 |
|
|
2020
Q4 | $106K | Sell |
18,450
-8,270
| -31% | -$62.6K | ﹤0.01% | 4521 |
|
|
2020
Q3 | $193K | Buy |
+26,720
| New | +$143K | ﹤0.01% | 3676 |
|
|
2019
Q1 | – | Sell |
-1,156
| Closed | -$12.3K | – | 5495 |
|
|
2018
Q4 | $9K | Buy |
+1,156
| New | +$11K | ﹤0.01% | 4316 |
|
|
2018
Q2 | – | Sell |
-3,475
| Closed | -$43.5K | – | 5572 |
|
|
2018
Q1 | $45K | Buy |
+3,475
| New | +$43.2K | ﹤0.01% | 3718 |
|
|
2017
Q3 | – | Sell |
-4,108
| Closed | -$27.8K | – | 5264 |
|
|
2017
Q2 | $24K | Buy |
+4,108
| New | +$17.5K | ﹤0.01% | 3876 |
|
Other funds holding CBAY
Group One Trading's CBAY Position: Q4 2023 in Review
Group One Trading sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 23,495 shares — an estimated $418K sold.
Group One Trading first reported a position in CBAY in Q2 2017 and held it in 11 quarters. The position peaked at $350K in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.
- Group One Trading reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
- Group One Trading sold 23,495 Cymabay Therapeutics shares in Q4 2023, an estimated $418K.
- Group One Trading first reported a position in Cymabay Therapeutics in Q2 2017 and held it in 11 quarters.
- Group One Trading's Cymabay Therapeutics position peaked at $350K in Q3 2023.
- 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.
Based on Group One Trading's 13F filing for Q4 2023, filed 14 Feb 2024.